Cyclized Peptide and Neuraminidase Inhibitor Composition for Influenza
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for influenza, including neuraminidase inhibitors, only partially inhibit virus proliferation and fail to effectively reduce existing viruses or alleviate severe symptoms like pulmonary inflammation, which can lead to complications.
Innovation Solution
A pharmaceutical composition combining a cyclized peptide with 7-17 adjacent amino acids, specifically the hexamer TX1EX2X3E, and a neuraminidase inhibitor, such as Zanamivir or Oseltamivir, to enhance therapeutic efficacy in treating influenza infections, particularly pulmonary inflammations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If neuraminidase inhibitors are used alone, then virus proliferation is partially inhibited, but therapeutic efficacy is insufficient and severe symptoms like pulmonary inflammation are not effectively reduced
Solution Approach 1:
The patent combines a cyclized peptide with neuraminidase inhibitor to create a pharmaceutical composition that synergistically reduces pulmonary inflammation and shortens disease duration, resolving the insufficiency of single-agent therapy
2Productivity
If existing treatments are used, then some virus proliferation is inhibited, but the duration of disease is prolonged and severe symptoms persist
Solution Approach 1:
The combination of cyclized peptide and neuraminidase inhibitor works synergistically to accelerate viral clearance and reduce disease duration, addressing both the recovery rate and time loss aspects
Data Source
AI summary
Described is a composition comprising a peptide which consists of 7-17 adjacent amino acids and comprises the hexamer TX1EX2X3E, where X1, X2, and X3 can be any natural or non-natural amino acid, and the peptide is cyclized and does not exhibit TNF receptor binding activity, and an inhibitor of viral neuraminidase.